Dynamic Critical Congenital Heart Screening With Addition of Perfusion Measurements

Description

The purpose of this study is to implement and externally validate an inpatient ML algorithm that combines pulse oximetry features for critical congenital heart disease (CCHD) screening.

Conditions

Congenital Heart Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to implement and externally validate an inpatient ML algorithm that combines pulse oximetry features for critical congenital heart disease (CCHD) screening.

Dynamic Critical Congenital Heart Screening With Addition of Perfusion Measurements

Dynamic Critical Congenital Heart Screening With Addition of Perfusion Measurements

Condition
Congenital Heart Disease
Intervention / Treatment

-

Contacts and Locations

Davis

UC Davis Medical Center, Davis, California, United States, 95616

Queens

Cohen Children's Medical Center, Queens, New York, United States, 11040

Salt Lake City

University of Utah Health Care, Salt Lake City, Utah, United States, 84102

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age \< 22 days
  • * Fetuses suspected to have congenital heart disease
  • * Newborns with suspected/confirmed critical congenital heart disease
  • * Asymptomatic newborn undergoing SpO2 screening for CCHD
  • * Echocardiogram completed prior to enrollment as the newborn would then no longer be considered "asymptomatic undergoing SpO2 screening for CCHD"
  • * For Newborns with confirmed/suspected congenital heart disease (CHD): a) Patent ductus arteriosus and/or atrial septal defect/patent foramen ovale without other defects, b) Corrective cardiac surgical or catheter intervention performed before enrollment or c) Current infusions of vasoactive medications other than prostaglandin therapy.

Ages Eligible for Study

0 Minutes to 21 Days

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of California, Davis,

Study Record Dates

2027-12-31